EA201692488A1 - Пептиды, выполняющие роль агонистов окситоцина - Google Patents

Пептиды, выполняющие роль агонистов окситоцина

Info

Publication number
EA201692488A1
EA201692488A1 EA201692488A EA201692488A EA201692488A1 EA 201692488 A1 EA201692488 A1 EA 201692488A1 EA 201692488 A EA201692488 A EA 201692488A EA 201692488 A EA201692488 A EA 201692488A EA 201692488 A1 EA201692488 A1 EA 201692488A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lower alkyl
group
hydrogen atom
hydroxyl group
cycloalkyl group
Prior art date
Application number
EA201692488A
Other languages
English (en)
Other versions
EA030296B1 (ru
Inventor
Катерина Биссанц
Конрад Блайгер
Канчан Чакраборти
Кристоф Грундшобер
Гоутам Саха
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of EA201692488A1 publication Critical patent/EA201692488A1/ru
Publication of EA030296B1 publication Critical patent/EA030296B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям формулыгде Rявляется атомом водорода, низшим алкилом, -СН-циклоалкильной группой или циклоалкильной группой; Rявляется атомом водорода, низшим алкилом, низшим алкилом, замещенным гидроксильной группой; или Rи Rвместе с атомами N и С, к которым они присоединены, могут образовывать пирролидиновое кольцо, необязательно замещенное одним или двумя атомами F или гидроксильной группой, или могут образовывать азетидиновое или пиперидиновое кольцо; Rявляется атомом водорода, низшим алкилом, низшим алкилом, замещенным гидроксильной группой, -(CH)-NH, бензильной группой, необязательно замещенной гидроксильной группой, фенильной группой, -СН-циклоалкильной группой или циклоалкильной группой; Rявляется атомом водорода или низшей алкильной группой; n равно 1; m равно 0 или 1; о имеет значение от 1 до 4; или к фармацевтически приемлемой соли присоединения кислоты, к рацемической смеси или к соответствующему энантиомеру и/или оптическим изомерам. Обнаружено, что представленные соединения являются агонистами окситоциновых рецепторов для лечения аутизма, стресса, включая посттравматическое стрессовое расстройство, тревоги, включая тревожные расстройства и депрессию, шизофрении, психиатрических расстройств и потери памяти, алкогольной абстиненции, лекарственной зависимости и для лечения синдрома Прадера-Вилли.
EA201692488A 2014-06-06 2015-06-03 Пептиды, выполняющие роль агонистов окситоцина EA030296B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14171440 2014-06-06
PCT/EP2015/062314 WO2015185584A1 (en) 2014-06-06 2015-06-03 Peptides as oxytocin agonists

Publications (2)

Publication Number Publication Date
EA201692488A1 true EA201692488A1 (ru) 2017-05-31
EA030296B1 EA030296B1 (ru) 2018-07-31

Family

ID=50932985

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692488A EA030296B1 (ru) 2014-06-06 2015-06-03 Пептиды, выполняющие роль агонистов окситоцина

Country Status (16)

Country Link
US (1) US20170081368A1 (ru)
EP (1) EP3152225B1 (ru)
JP (1) JP6535688B2 (ru)
KR (1) KR20170004014A (ru)
CN (1) CN106459156A (ru)
AU (1) AU2015270564A1 (ru)
CA (1) CA2950493A1 (ru)
CL (1) CL2016003076A1 (ru)
CR (1) CR20160562A (ru)
EA (1) EA030296B1 (ru)
IL (1) IL248625A0 (ru)
MX (1) MX2016015877A (ru)
PE (1) PE20170427A1 (ru)
PH (1) PH12016502251A1 (ru)
SG (1) SG11201610221WA (ru)
WO (1) WO2015185584A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3666258T1 (sl) 2014-09-19 2024-04-30 Ferring Bv Postopek zdravljenja Prader-Willijevega sindroma
US20190135859A1 (en) 2017-08-11 2019-05-09 Ferring B.V. Method of manufacturing a pharmaceutical composition
JP2020530456A (ja) 2017-08-11 2020-10-22 フェリング ベスローテン フェンノートシャップ 医薬組成物を製造する方法
EP3852723A4 (en) 2018-09-20 2022-06-29 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
TW202034899A (zh) 2018-09-20 2020-10-01 克里斯托弗 Ｓ 布萊恩特 卡貝縮宮素藥品及其製備方法
CN113801200B (zh) * 2021-09-28 2023-07-25 浙江湃肽生物有限公司 一种卡贝缩宫素的制备方法
WO2024044633A2 (en) * 2022-08-23 2024-02-29 Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) Oxytocin derivatives and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483794A (en) * 1983-05-10 1984-11-20 Ceskoslovenska Akademie Ved Analogs of neurohypophysial hormones
KR20070022753A (ko) * 2004-05-26 2007-02-27 화이자 인코포레이티드 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도
FR2875499B1 (fr) * 2004-09-20 2006-10-27 Sanofi Aventis Sa Nouveaux derives pyridiniques d'indolin-2-one, leur preparation et leur application en therapeutique
EA026578B1 (ru) * 2007-01-22 2017-04-28 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
EP2260053B1 (en) * 2008-03-31 2014-05-14 Ferring BV Oxytocin analogues
WO2010034656A1 (en) * 2008-09-23 2010-04-01 F. Hoffmann-La Roche Ag Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine d3 receptors
MX2011011477A (es) * 2009-05-05 2011-11-18 Hoffmann La Roche Derivados de isoxazol-piridazina.
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
EP2482835B1 (en) * 2009-10-01 2014-07-02 The University Of Sydney Therapy and prevention of problem drinking
WO2012016229A2 (en) 2010-07-30 2012-02-02 The Regents Of The University Of California Oxytocin treatment to improve memory and modify blood glucose

Also Published As

Publication number Publication date
KR20170004014A (ko) 2017-01-10
EA030296B1 (ru) 2018-07-31
CA2950493A1 (en) 2015-12-10
PE20170427A1 (es) 2017-04-26
SG11201610221WA (en) 2017-01-27
AU2015270564A1 (en) 2016-11-17
MX2016015877A (es) 2017-03-27
CL2016003076A1 (es) 2017-08-11
JP2017518313A (ja) 2017-07-06
IL248625A0 (en) 2017-01-31
PH12016502251A1 (en) 2017-02-06
CR20160562A (es) 2017-01-06
EP3152225A1 (en) 2017-04-12
WO2015185584A1 (en) 2015-12-10
US20170081368A1 (en) 2017-03-23
JP6535688B2 (ja) 2019-06-26
CN106459156A (zh) 2017-02-22
EP3152225B1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
EA201692488A1 (ru) Пептиды, выполняющие роль агонистов окситоцина
NZ708175A (en) Peptides as oxytocin agonists
CL2018000036A1 (es) Derivados etinilo
MX2015017491A (es) Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona.
PH12016502231B1 (en) Indolin-2-one or pyrrolo-pyridin-2-one derivatives
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
MX2015008830A (es) Agonistas del receptor de oxitocina para el tratamiento de enfermedades del sistema nervioso central.
AR099047A1 (es) Derivados etinilo
AR097721A1 (es) Derivados de etinilo
PH12016502232A1 (en) Peptides as oxytocin agonists
AR106588A1 (es) Derivados de indolin-2-ona para el tratamiento de enfermedades del snc
AR104863A1 (es) Derivados imidazol
AR105327A1 (es) Derivados de imidazol
AR103952A1 (es) Derivados de pirimidina-diona
PH12015500261A1 (en) Arylethynyl pyrimidines
AR099300A1 (es) Hexahidrofuropirroles como inhibidores de pde1
TH167739B (th) เปปไทด์เป็นตัวทำการออกซีโทซิน
TH167739A (th) เปปไทด์เป็นตัวทำการออกซีโทซิน
AR098802A1 (es) Quinazolin-thf-aminas como inhibidores de pde1

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU